Do analysts recommend SNOA or ATXI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend ATXI or PULM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Pulmatrix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, ATXI or PULM?

Pulmatrix is trading at a lower price-to-earnings ratio than Avenue Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avenue Therapeutics N/A N/A -$10.38M -$0.85 N/A Pulmatrix N/A N/A -$5.16M -$1.10 N/A

Is ATXI or PULM more profitable?

Pulmatrix's return on equity of -125.65% beat Avenue Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Avenue Therapeutics N/A -471.57% -296.50% Pulmatrix N/A -125.65% -95.19%

Do analysts prefer ATXI or EOCN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, ATXI or EOCN?

Avenue Therapeutics is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avenue Therapeutics N/A N/A -$10.38M -$0.85 N/A Galmed Pharmaceuticals N/A N/A -$10.31M -$15.18 N/A

Is ATXI or EOCN more profitable?

Galmed Pharmaceuticals' return on equity of -73.68% beat Avenue Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Avenue Therapeutics N/A -471.57% -296.50% Galmed Pharmaceuticals N/A -73.68% -60.88%

Do analysts prefer NCNA or ATXI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, NCNA or ATXI?

Avenue Therapeutics is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NuCana N/A N/A -$38.71M -$3.81 N/A Avenue Therapeutics N/A N/A -$10.38M -$0.85 N/A

Is NCNA or ATXI more profitable?

NuCana's return on equity of -41.90% beat Avenue Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets NuCana N/A -41.90% -33.69% Avenue Therapeutics N/A -471.57% -296.50%

Do analysts prefer INM or ATXI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is INM or ATXI more profitable?

InMed Pharmaceuticals' return on equity of -156.08% beat Avenue Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets InMed Pharmaceuticals N/A -156.08% -123.90% Avenue Therapeutics N/A -471.57% -296.50%

Avenue Therapeutics (ATXI) Competitors

$0.43 0.00 (0.00%)

As of 10/14/2026 12:02 PM Eastern

Compare

ATXI vs. SNOA, PULM, GLMD, NCNA, and INM

Should you buy Avenue Therapeutics stock or one of its competitors? Avenue Therapeutics's main competitors and comparable companies include Sonoma Pharmaceuticals (SNOA), Pulmatrix (PULM), Galmed Pharmaceuticals (GLMD), NuCana (NCNA), and InMed Pharmaceuticals (INM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Avenue Therapeutics compare to Sonoma Pharmaceuticals?

Sonoma Pharmaceuticals (NASDAQ:SNOA) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.

Sonoma Pharmaceuticals has higher revenue and earnings than Avenue Therapeutics. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Avenue Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sonoma Pharmaceuticals	$19.53M	0.28	-$3.17M	-$1.22	N/A
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.85	N/A

2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are held by institutional investors. 1.0% of Sonoma Pharmaceuticals shares are held by company insiders. Comparatively, 8.6% of Avenue Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Avenue Therapeutics has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -10.33%. Sonoma Pharmaceuticals' return on equity of -21.41% beat Avenue Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sonoma Pharmaceuticals	-10.33%	-21.41%	-6.08%
Avenue Therapeutics	N/A	-471.57%	-296.50%

Sonoma Pharmaceuticals has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market. Comparatively, Avenue Therapeutics has a beta of -0.23, suggesting that its stock price is 123% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sonoma Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Avenue Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Sonoma Pharmaceuticals had 1 more articles in the media than Avenue Therapeutics. MarketBeat recorded 1 mentions for Sonoma Pharmaceuticals and 0 mentions for Avenue Therapeutics. Sonoma Pharmaceuticals' average media sentiment score of 1.82 beat Avenue Therapeutics' score of 0.00 indicating that Sonoma Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Sonoma Pharmaceuticals	Very Positive
Avenue Therapeutics	Neutral

Summary

Sonoma Pharmaceuticals beats Avenue Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Avenue Therapeutics compare to Pulmatrix?

Avenue Therapeutics (NASDAQ:ATXI) and Pulmatrix (NASDAQ:PULM) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avenue Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Pulmatrix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Pulmatrix's return on equity of -125.65% beat Avenue Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avenue Therapeutics	N/A	-471.57%	-296.50%
Pulmatrix	N/A	-125.65%	-95.19%

Pulmatrix is trading at a lower price-to-earnings ratio than Avenue Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.85	N/A
Pulmatrix	N/A	N/A	-$5.16M	-$1.10	N/A

17.3% of Avenue Therapeutics shares are owned by institutional investors. Comparatively, 11.8% of Pulmatrix shares are owned by institutional investors. 8.6% of Avenue Therapeutics shares are owned by company insiders. Comparatively, 0.6% of Pulmatrix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Pulmatrix had 1 more articles in the media than Avenue Therapeutics. MarketBeat recorded 1 mentions for Pulmatrix and 0 mentions for Avenue Therapeutics. Pulmatrix's average media sentiment score of 1.23 beat Avenue Therapeutics' score of 0.00 indicating that Pulmatrix is being referred to more favorably in the news media.

Company	Overall Sentiment
Avenue Therapeutics	Neutral
Pulmatrix	Positive

Avenue Therapeutics has a beta of -0.23, indicating that its share price is 123% less volatile than the broader market. Comparatively, Pulmatrix has a beta of 1.93, indicating that its share price is 93% more volatile than the broader market.

Summary

Pulmatrix beats Avenue Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Avenue Therapeutics compare to Galmed Pharmaceuticals?

Avenue Therapeutics (NASDAQ:ATXI) and Galmed Pharmaceuticals (NASDAQ:EOCN) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.

Avenue Therapeutics has a beta of -0.23, meaning that its share price is 123% less volatile than the broader market. Comparatively, Galmed Pharmaceuticals has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avenue Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Galmed Pharmaceuticals had 1 more articles in the media than Avenue Therapeutics. MarketBeat recorded 1 mentions for Galmed Pharmaceuticals and 0 mentions for Avenue Therapeutics. Galmed Pharmaceuticals' average media sentiment score of 0.75 beat Avenue Therapeutics' score of 0.00 indicating that Galmed Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Avenue Therapeutics	Neutral
Galmed Pharmaceuticals	Positive

Avenue Therapeutics is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.85	N/A
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$15.18	N/A

17.3% of Avenue Therapeutics shares are owned by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. 8.6% of Avenue Therapeutics shares are owned by company insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Galmed Pharmaceuticals' return on equity of -73.68% beat Avenue Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avenue Therapeutics	N/A	-471.57%	-296.50%
Galmed Pharmaceuticals	N/A	-73.68%	-60.88%

Summary

Galmed Pharmaceuticals beats Avenue Therapeutics on 9 of the 10 factors compared between the two stocks.

How does Avenue Therapeutics compare to NuCana?

NuCana (NASDAQ:NCNA) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

In the previous week, NuCana had 1 more articles in the media than Avenue Therapeutics. MarketBeat recorded 1 mentions for NuCana and 0 mentions for Avenue Therapeutics. NuCana's average media sentiment score of 1.82 beat Avenue Therapeutics' score of 0.00 indicating that NuCana is being referred to more favorably in the media.

Company	Overall Sentiment
NuCana	Very Positive
Avenue Therapeutics	Neutral

44.0% of NuCana shares are owned by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are owned by institutional investors. 31.2% of NuCana shares are owned by company insiders. Comparatively, 8.6% of Avenue Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Avenue Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

NuCana has a beta of 2.3, indicating that its stock price is 130% more volatile than the broader market. Comparatively, Avenue Therapeutics has a beta of -0.23, indicating that its stock price is 123% less volatile than the broader market.

NuCana's return on equity of -41.90% beat Avenue Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NuCana	N/A	-41.90%	-33.69%
Avenue Therapeutics	N/A	-471.57%	-296.50%

Avenue Therapeutics is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NuCana	N/A	N/A	-$38.71M	-$3.81	N/A
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.85	N/A

Summary

NuCana beats Avenue Therapeutics on 8 of the 10 factors compared between the two stocks.

How does Avenue Therapeutics compare to InMed Pharmaceuticals?

InMed Pharmaceuticals (NASDAQ:INM) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

20.1% of InMed Pharmaceuticals shares are owned by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are owned by institutional investors. 0.9% of InMed Pharmaceuticals shares are owned by insiders. Comparatively, 8.6% of Avenue Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

InMed Pharmaceuticals' return on equity of -156.08% beat Avenue Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMed Pharmaceuticals	N/A	-156.08%	-123.90%
Avenue Therapeutics	N/A	-471.57%	-296.50%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Avenue Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

InMed Pharmaceuticals has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, Avenue Therapeutics has a beta of -0.23, indicating that its share price is 123% less volatile than the broader market.

In the previous week, InMed Pharmaceuticals had 6 more articles in the media than Avenue Therapeutics. MarketBeat recorded 6 mentions for InMed Pharmaceuticals and 0 mentions for Avenue Therapeutics. InMed Pharmaceuticals' average media sentiment score of 0.42 beat Avenue Therapeutics' score of 0.00 indicating that InMed Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
InMed Pharmaceuticals	Neutral
Avenue Therapeutics	Neutral

Avenue Therapeutics has lower revenue, but higher earnings than InMed Pharmaceuticals. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than Avenue Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMed Pharmaceuticals	$4.94M	0.88	-$12.56M	-$1.64	N/A
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.85	N/A

Summary

InMed Pharmaceuticals beats Avenue Therapeutics on 8 of the 12 factors compared between the two stocks.

Get Avenue Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATXI vs. The Competition

Export

Metric	Avenue Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.42M	$12.66B	$7.44B	$12.94B
Dividend Yield	N/A	2.63%	2.52%	19.59%
P/E Ratio	0.02	805.30	275.00	25.39
Price / Sales	N/A	838.52	569.10	75.48
Price / Cash	N/A	84.08	76.68	52.75
Price / Book	0.22	9.32	10.32	6.02
Net Income	-$10.38M	$2.83B	$3.49B	$380.68M
7 Day Performance	0.05%	-3.32%	-2.50%	-3.01%
1 Month Performance	-40.28%	-7.19%	-6.83%	-5.61%
1 Year Performance	-41.89%	-5.39%	1.85%	-5.24%

Avenue Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATXI Avenue Therapeutics	N/A	$0.43 flat	N/A	-49.0%	$1.42M	N/A	0.02	4
SNOA Sonoma Pharmaceuticals	0.7981 of 5 stars	$1.16 -4.9%	N/A	-71.5%	$5.56M	$19.53M	N/A	260
PULM Pulmatrix	1.1117 of 5 stars	$1.50 +0.6%	N/A	-72.0%	$5.47M	$7.81M	N/A	2	Gap Up
GLMD Galmed Pharmaceuticals	N/A	$4.59 -0.9%	N/A	N/A	$4.78M	N/A	N/A	20	Gap Down High Trading Volume
NCNA NuCana	1.4772 of 5 stars	$1.13 -0.9%	N/A	-82.1%	$4.70M	N/A	N/A	11

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATXI) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avenue Therapeutics (ATXI) Competitors

ATXI vs. SNOA, PULM, GLMD, NCNA, and INM

How does Avenue Therapeutics compare to Sonoma Pharmaceuticals?

Summary

How does Avenue Therapeutics compare to Pulmatrix?

Summary

How does Avenue Therapeutics compare to Galmed Pharmaceuticals?

Summary

How does Avenue Therapeutics compare to NuCana?

Summary

How does Avenue Therapeutics compare to InMed Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATXI vs. The Competition

Avenue Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avenue Therapeutics (ATXI) Competitors

ATXI vs. SNOA, PULM, GLMD, NCNA, and INM

How does Avenue Therapeutics compare to Sonoma Pharmaceuticals?

Which has stronger earnings & valuation, SNOA or ATXI?

Do institutionals and insiders hold more shares of SNOA or ATXI?

Is SNOA or ATXI more profitable?

Which has more volatility and risk, SNOA or ATXI?

Do analysts recommend SNOA or ATXI?

Does the media prefer SNOA or ATXI?

Summary

How does Avenue Therapeutics compare to Pulmatrix?

Do analysts recommend ATXI or PULM?

Is ATXI or PULM more profitable?

Which has preferable valuation & earnings, ATXI or PULM?

Do institutionals & insiders believe in ATXI or PULM?

Does the media refer more to ATXI or PULM?

Which has more volatility & risk, ATXI or PULM?

Summary

How does Avenue Therapeutics compare to Galmed Pharmaceuticals?

Which has more risk and volatility, ATXI or EOCN?

Do analysts prefer ATXI or EOCN?

Does the media favor ATXI or EOCN?

Which has higher valuation and earnings, ATXI or EOCN?

Do insiders & institutionals have more ownership in ATXI or EOCN?

Is ATXI or EOCN more profitable?

Summary

How does Avenue Therapeutics compare to NuCana?

Does the media refer more to NCNA or ATXI?

Do institutionals and insiders hold more shares of NCNA or ATXI?

Do analysts prefer NCNA or ATXI?

Which has more volatility and risk, NCNA or ATXI?

Is NCNA or ATXI more profitable?

Which has better valuation & earnings, NCNA or ATXI?

Summary

How does Avenue Therapeutics compare to InMed Pharmaceuticals?

Do institutionals & insiders hold more shares of INM or ATXI?

Is INM or ATXI more profitable?

Do analysts prefer INM or ATXI?

Which has more risk & volatility, INM or ATXI?

Does the media refer more to INM or ATXI?

Which has higher earnings and valuation, INM or ATXI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATXI vs. The Competition

Avenue Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools